Short-term Effect of Intensive Insulin Therapy on Incretin Secretion
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00776243 |
Recruitment Status
:
Completed
First Posted
: October 21, 2008
Last Update Posted
: May 12, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Type 2 Diabetes |
Study Type : | Observational |
Estimated Enrollment : | 30 participants |
Observational Model: | Case Control |
Time Perspective: | Prospective |
Official Title: | Short-term Effect of Intensive Insulin Therapy on Incretin Secretion |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | December 2009 |
Actual Study Completion Date : | December 2009 |

Group/Cohort |
---|
wDM
Early diabetes
|
pDM
Poorly controlled diabetic patients
|
- Difference of incretin secretion before and after intensive insulin therapy [ Time Frame: 2 months ]
- Difference in incretin secretion according to the duration of diabetes [ Time Frame: basal ]
- Factors affecting incretin secretion [ Time Frame: basal ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 70 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
- Subjects with normal glucose tolerance
- Early diabetic patients with disease duration of less than 5years
- Uncontrolled diabetic patients
Inclusion Criteria:
- type 2 diabetic patients with disease duration of less than 15years
- age of 20-70 years
- BMI 22-27
- HbA1c 9-13%
- patients willing to receive intensive glucose control
-
patients who are able to monitor their glucose level at home
- for normal glucose tolerance group : NGT subjects with same range of age and BMI
- for early diabetes group : patients with diabetic duration of less than 5 years and HbA1c level less than 7.5% for at least last 6 months
Exclusion Criteria:
- previous history of insulin treatment
- patients taking alpha-glucosidase inhibitor or thiazolidinedione
- serum creatinine >= 1.5 mg/dL
- hemoglobin < 10 g/dL
- AST/ALT greater than 3 times normal range
- ischemic heart disease, congestive heart failure (NYHA grade >=2)
- chronic renal failure, proliferative diabetic retinopathy, CVA
- patients with gastroparesis or taking medications altering gastric motility
- usage of steroid or other agents affecting glucose metabolism
- pregnant or breast-feeding women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776243
Korea, Republic of | |
Division of Endocrinology and Metabolism, St.Vincent's Hospital | |
Suwon, Kyonggi-do, Korea, Republic of, 442-723 | |
Division of Endocrinology and Metabolism, Kangnam St.Mary's Hospital | |
Seoul, Korea, Republic of, 137-701 |
Principal Investigator: | Kun-Ho Yoon, M.D., Ph.D. | The Catholic University of Korea |
Publications:
Responsible Party: | Kun-Ho Yoon, Kangnam St.Mary's hospital |
ClinicalTrials.gov Identifier: | NCT00776243 History of Changes |
Other Study ID Numbers: |
KCMC08MI168 VCMC08OT066 |
First Posted: | October 21, 2008 Key Record Dates |
Last Update Posted: | May 12, 2010 |
Last Verified: | October 2009 |
Keywords provided by The Catholic University of Korea:
incretin GLP-1 GIP intensive insulin therapy |
Additional relevant MeSH terms:
Insulin Incretins Hypoglycemic Agents |
Physiological Effects of Drugs Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |